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Genetic cholestasis: Lessons
from the molecular physiology
of bile formation
Peter LM Jansen MD, Michael Müller PhD
The secretion of solutes in bile depends on the activity oftransporter proteins in the sinusoidal and canalicular
membranes of hepatocytes. Bile acids, bilirubin and various
other endogenous metabolites are delivered to the liver via
the portal blood. Sinusoidal membranes of the hepatocytes
contain carrier proteins that are capable of extracting plasma
protein-bound compounds, which are taken up by the liver.
In the liver, many of these metabolites are further metabo-
lized in preparation for biliary secretion. For example, un-
conjugated bilirubin cannot be secreted as such into bile, but
after conjugation with glucuronic acid, bilirubin becomes a
substrate for transporter proteins in the canalicular mem-
brane of the hepatocyte.
Bile formation starts with the active transport of solutes
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MINI-REVIEW
PLM Jansen, M Müller. Genetic cholestasis: Lessons from the
molecular physiology of bile formation. Can J Gastroenterol
2000;14(3):233-238. Progressive familial intrahepatic cholesta-
sis (PFIC) is a group of severe genetic cholestatic liver diseases of
early life. PFIC types 1 and 2 are characterized by cholestasis and a
low to normal serum gamma-glutamyltransferase (GGT) activity,
whereas in PFIC type 3, the serum GGT activity is elevated. PFIC
types 1 and 2 occur due to mutations in loci at chromosome 18 and
chromosome 2, respectively. The pathophysiology of PFIC type 1
is not well understood. PFIC types 2 and 3 are caused by transport
defects in the liver affecting the hepatobiliary secretion of bile ac-
ids and phospholipids, respectively. Benign recurrent intrahepatic
cholestasis (BRIC) is linked to a mutation in the same familial in-
trahepatic cholestasis 1 locus at chromosome 18. Defects of bile
acid synthesis may be difficult to differentiate from these transport
defects.
Intrahepatic cholestasis of pregnancy (ICP) appears to be related
to these cholestatic diseases. For example, heterozygosity in fami-
lies with PFIC type 3 is associated with ICP, but ICP has also been
reported in families with BRIC.
In Dubin-Johnson syndrome there is no cholestasis; only the hepa-
tobiliary transport of conjugated bilirubin is affected. This, there-
fore, is a mild disease, and patients have a normal lifespan.
Key Words: Bile; Bile salt export pump; Cholestasis; Dubin-Johnson
syndrome; P-glycoprotein; Progressive familial intrahepatic cholestasis
Cholostase génétique : Les leçons de la
physiologie moléculaire de la formation
biliaire
RÉSUMÉ : La cholostase intra-hépatique familiale progressive (CIFP)
regroupe des maladies hépatiques cholostatiques génétiques graves
survenant tôt au cours de la vie. Les CIFP de types I et II se caractérisent par
une cholostase et une activité de faible à normale de la
gamma-glutamyltransférase (GGT) sérique, alors que la CIFP de type III
s’accompagne d’une activité accrue de la GGT sérique. La CIFP de types I
et II survient suite à des mutations des loci situés dans les chromosomes 18
et 2, respectivement. La physiopathologie de la CIFP de type I est encore
mal élucidée. La CIFP de types II et III est causée par une anomalie du
transport hépatique affectant la sécrétion hépatobiliaire des acides biliaires
et des phospholipides respectivement. La cholostase intra-hépatique
récurrente bénigne (CIRB) est liée à une mutation du même locus FIC-1
sur le chromosome 18. Les anomalies de synthèse de l’acide biliaire
peuvent être difficiles à distinguer de ces anomalies de transport.
La cholostase intrahépatique associée à la grossesse (CIHP) semble liée à
ces maladies cholostatiques. Par exemple, l’hétérozygotie notée dans les
familles où sévit la CIFP de type III est associée à la CIHP, mais la CIHP a
aussi été observée dans les famille touchées par la CIRB.
Dans le syndrome de Dubin-Johnson, il n’y a pas de cholostase, seul le
transport hépatobiliaire de la bilirubine conjuguée est affecté. Il s’agit donc
d’une maladie bénigne et les patients ont une espérance de vie normale.
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from hepatocytes across the plasma membrane into the bile
canaliculus. For this active secretion, the hepatocyte is
equipped with a number of transmembrane transporter pro-
teins. These proteins are able to pump solutes against a steep
concentration gradient into bile. Many of these transporters
have been cloned. This review concentrates on genetic cho-
lestasis. This interest is motivated by the fact that genetic
cholestatic liver diseases are experiments of nature that
prove the importance of hepatic transport and hepatic trans-
porter proteins.
MOLECULAR PHYSIOLOGY
For the hepatic uptake of bile salts, organic anions and cati-
ons, the basolateral membrane of the hepatocyte contains a
sodium-dependent taurocholate cotransporter protein
(NTCP), organic anion transporters (OATP in humans and
oatpl and oatp2 in rodents) and an organic cation trans-
porter (OCT1) (1-3) (Figure 1). These transporters are not
directly ATP-dependent for their function. They function as
facilitators for the diffusion of a broad but specified group of
substrates. In the circulation, many cholephilic compounds
are firmly bound to plasma proteins. The plasma membrane
transporters may play a role in the hepatic extraction of
these compounds. As yet, no genetic diseases have been
identified in which these proteins are involved. Among pa-
tients with unconjugated hyperbilirubinemia, there may be a
subgroup with an uptake defect for unconjugated bilirubin
(4,5). This has not been studied at the molecular level.
Transporters, mediating the secretion from liver to bile,
belong to the family of ATP-binding cassette proteins. This
family, of which about 500 members are cloned, is ubiquitous
in nature and is found in prokaryotes, nematodes, insects,
plants and mammals. In humans, members of this trans-
porter protein family include the P-glycoproteins (MDRs),
the multidrug resistance proteins (MRPs), the cystic fibrosis
transmembrane regulator, the transporter associated with
antigen presentation (TAP) proteins and a peroxisomal long
chain fatty acid transporter. In the liver, the canalicular
membrane is particularly rich in ABC transporters; the most
important components are the bile salt export pump (BSEP)
(also called sister of P-glycoprotein), the canalicular multis-
pecific organic anion transporter (cMOAT or MRP2), a ca-
nalicular phosphatidylcholine translocator (MDR3) and the
MDR1 P-glycoprotein, a transporter for drugs and other hy-
drophobic compounds (2). In cancer cells, the overexpressed
MDR1 P-glycoprotein is actively engaged in the extrusion of
drugs and thus contributes to their MDR phenotype.
Bile salts, phospholipids, cholesterol and glutathione are
the dominant solutes of bile. Bile salts in bile participate in
the enterohepatic circulation. This mechanism, which can
be described as a series of bile salt pumps, is aimed at the con-
servation of bile salts. The ATP-dependent canalicular
BSEP of the periportal hepatocytes has a dominant role in
the enterohepatic circulation of bile salts. Bile salts enter the
liver via the portal blood and are taken up and secreted by
the hepatocytes of acinar zone I, the periportal hepatocytes.
Hepatocytes of zone III, the centrilobular hepatocytes,
mainly secrete newly formed bile salts. NTCP and the ileum
bile salt transporter (IBST) also play a role in the enterohe-
patic circulation of bile salts. NTCP is the protein responsi-
ble for hepatic uptake of bile salts. IBST is the main
intestinal bile salt transporter – the only intestinal bile salt
transporter cloned thus far. Mutations in the iBST gene lead
to persistent bile salt diarrhea (6,7). Mutations of the NTCP
gene have not been identified.
The movement of phosphatidylcholine through the ca-
nalicular membrane is catalyzed by MDR3, which, like
BSEP, is an ATP-dependent P-glycoprotein. In rodents,
MDR3 is called mdr2. The secretion of cholesterol follows
that of phosphatidylcholine and bile salts. An mdr2–/–
(knockout) mouse cannot secrete phosphatidylcholine, and
as a consequence there is hardly any biliary cholesterol secre-
tion (8). This does not necessarily mean that mdr2/MDR3 is
also a cholesterol carrier but that phospholipid secretion is a
minimal requirement for cholesterol secretion. Other com-
ponents of the phospholipid and cholesterol secretory path-
ways include the intracellular binding proteins, phosphati-
dylcholine transfer protein and sterol-carrier protein 2.
Hepatobiliary transport of glutathione, the glucuronide-
conjugates of bilirubin, the glutathione-, glucuronide- and
sulphate-conjugates of drugs, and many other compounds, is
mediated by cMOAT, which is also called MRP2 (9-11).
PROGRESSIVE FAMILIAL INTRAHEPATIC
CHOLESTASIS TYPE 1
Progressive familial intrahepatic cholestasis (PFIC) is a
group of diseases characterized by congenital cholestasis
(Table 1). Byler disease, a well known member of this group,
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Figure 1) Hepatic transport pumps. Two hepatocytes are shown with
three canaliculi. Each canaliculus is surrounded by specialized membrane
domains of the hepatocyte and is sealed off by tight junctions. The
specialized membrane domains contain the ATP-dependent transport-
ers, canalicular multispecific organic anion transporter/multidrug
resistant-associated protein 2, bile salt export pump (BSEP), MDR1
and MDR3 pumping organic anions, bile salts, hydrophobic cations and
phosphatidylcholine from liver to bile. The sinusoidal membrane contains
transporters for the uptake of organic anions (organic anion transporter
protein [OATP]), bile salts (sodium-dependent taurocholate cotrans-
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is also called PFIC type 1. Byler disease was founded by Jacob
Byler, a farmer of Amish ancestry who settled in Pennsylva-
nia in the late 18th century. Patients initially have recurrent
cholestasis, but cholestasis very soon becomes persistent
(12). Bile of these children is deficient in bile acids and par-
ticularly devoid of chenodeoxycholic acid. The liver biopsy
shows bland cholestasis without much bile duct prolifera-
tion. Clinically, the disease is characterized by jaundice, di-
arrhea, decreased growth and a relatively low to normal
serum gamma-glutamyltransferase (GGT) activity, elevated
serum bile acid levels and an elevated alkaline phosphatase
level. Positional cloning studies in a large Byler kindred re-
vealed a mutation in a locus at chromosome 18q21-q22, the
FIC-1 locus (13-15). Bull et al (16) suggested that this muta-
tion affects a member of the family of P-type ATPases (16).
This family is comprised of P1-ATPases, which mediate
metal transport including copper, and P2-ATPases for the
transport of cations such as hydrogen/potassium-ATPase in
the gastric mucosa. The P-ATPase involved in PFIC type 1
appears to have homology to a putative ATP-dependent
aminophospholipid transporter. This transporter may act as
a flippase, moving phosphatidylserine and phosphatidyl-
ethanolamine from the outer membrane leaflet to the inner
leaflet, thus establishing an assymetric distribution of phos-
pholipids in the plasma membrane. This organization may be
needed either for the function of transmembrane transport-
ers or for the membrane insertion of newly synthesized trans-
porter proteins. However, the P-ATPase that is putatively
implicated in PFIC-1 is not expressed in hepatocytes but
seems more important in cholangiocytes, the intestine and
the pancreas (16). Although this explains the extrahepatic
manifestations such as pancreas insufficiency, sweat electro-
lyte abnormalities and intestinal malabsorption, it is difficult
to equate with cholestasis as the most prominent symptom.
The pathophysiology of PFIC type 1 would be more compati-
ble with hepatic dysregulation of bile salt secretion or with
intestinal bile salt malabsorption with, as a consequence,
formation of toxic monohydroxy bile salts in the colon. This
argument is supported by the fact that benign recurrent in-
trahepatic cholestasis (BRIC), characterized by recurrent
bouts of cholestasis and intervals of entirely normal liver
function, is genetically related to Byler disease (17). Both
BRIC and PFIC type 1 are associated with mutations in the
FIC-1 gene (15-18). However, neither all patients with a
PFIC-phenotype, nor all patients with BRIC, have a muta-
tion at the chromosome 18 FIC-1 locus (14-19).
PFIC TYPE 2
PFIC type 2 is characterized by persistent neonatal cholesta-
sis. It often presents as neonatal hepatitis. As with PFIC type
1, the liver histology of patients with PFIC type 2 does not
show much bile duct proliferation, and the general picture is
one of bland cholestasis. As in PFIC type 1, serum bile acids
and alkaline phosphatase activity are elevated and GGT ac-
tivity is normal. Strautnieks et al (20,21) mapped the gene
defect for this disease to a locus at chromosome 2q24, the
FIC-2 locus (20,21). This disease appears to result from a de-
fect of hepatobiliary bile salt transport.
Bile salts are secreted into bile against a very steep con-
centration gradient. Therefore, it is not surprising that bile
salt secretion is an ATP-dependent process. This was known
many years before the implicated transporter was cloned.
Concentrative bile salt transport seems to be a specific liver
function. For example, ileal bile salt transport is not concen-
trative but downhill from the bile salt-rich intestinal lumen
to the blood. Recently, a candidate protein for the canalicu-
lar bile salt transport has been cloned (22,23). It belongs to
the MDR/TAP subfamily of ABC-transporter proteins and is
called the BSEP. In humans, this protein is encoded by a
gene on chromosome 2q24, the locus to which PFIC type 2
has been mapped. The mutations of the BSEP gene identi-
fied thus far are shown in Table 2. Strautnieks et al (20)
found single nucleotide substitutions (nonsense and mis-
sense mutations), deletions and insertions. Figure 2 shows
sites in the BSEP protein that are predicted to be affected by
mutations.
PFIC TYPE 3
Deleuze et al (24) and de Vree et al (25) characterized a third
type of PFIC, PFIC type 3. In contrast with patients with
PFIC type 1, BRIC and PFIC type 2, patients with PFIC type
3 have a high serum GGT activity. This disease is character-
ized by pruritus followed by jaundice and cirrhosis. Patients
with PFIC type 3 produce bile salt-containing bile without
Can J Gastroenterol Vol 14 No 3 March 2000 235
Genetic cholestasis
TABLE 1
Characteristics of progressive familial intrahepatic cholestasis (PFIC)
Disease Chromosome Defect Pathology Symptoms
PFIC type 1 18q21-q22 P-type-ATPase Bland cholestasis Cholestasis, stunted growth,
diarrhea, pancreas insufficiency
PFIC type 2 2q24 Canalicular bile salt export Frequently starts as neonatal
hepatitis, later bland cholestasis
Neonatal hepatitis, cholestasis,
stunted growth
PFIC type 3 7q21 Canalicular phosphatidylcholine
translocator-MDR3
Impressive bile duct proliferation Pruritis , cholestasis
Dubin-Johnson syndrome 10q24 cMOAT/MRP2 Black hepatic pigment in
otherwise normal liver
Mild hyperbilirubinemia
CMOAT Canalicular multispecific organic anion transporter; MRP Multidrug resistance-associated protein
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phospholipids. The histological abnormalities of these pa-
tients and those of the mdr2–/– knockout mice are remarka-
bly similar. They consist of periportal inflammation,
extensive bile duct proliferation, feathery degeneration of
hepatocytes, fibrosis and, in the knockout mice, malignancy
of the liver. The hypothesis is that this histological picture is
due to the cytotoxicity of bile salts, which in normal bile is
antagonized by phospholipids.
Two patients described by de Vree et al (25) lacked
MDR3 in the liver. Reverse transcriptase polymerase chain
236 Can J Gastroenterol Vol 14 No 3 March 2000
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Figure 2) Mutations in the bile salt export pump (BSEP). The structure
of BSEP in the canalicular membrane is shown with indications of the
various mutations reported by Strautnieks et al (21). BSEP is proposed
to have 12 membrane-spanning domains. ABC ‘signatures’ (ABC) and
Walker A and B (A and B) motifs together form the nucleotide-binding
folds, which are present in duplicate. bp del Base pair deletion; bp ins
Base pair insertion
TABLE 2
Mutations in the bile salt export pump gene (BSEP)
Codon Nucleotide Amino acid














*Strautnieks et al (14) found homozygous missense mutations in seven
families with progressive familial intrahepatic cholestasis (PFIC) type 2: an
adenine (A) to guanine (G) transition at nucleotide 890 led to a glutathione
(Glu) 297 to glycine (Gly) substitution in the intracellular loop between
transmembrane spans 4 and 5. Heterozygous missense mutations were
found in 6 families; †In addition, cytosine (C) to thymine (T) transitions at
nucleotide 1723, resulting in an arginine (Arg) 575 to terminal (Term) sub-
stitution, were found with premature truncation of the BSEP protein. A
Latin American family carried the same mutation in homozygous form; in
the Belgian family, the mutation was heterozygous and the mutation on
the other allele was not identified; ‡In one family, the PFIC2 phenotype
was associated with homozygosity for insertion of one nucleotide, a C, be-
tween nucleotides 3767 and 3768. This resulted in a change in amino acid
1256, with the introduction of 39 novel amino acids followed by trunca-















Figure 3) Progressive familial intrahepatic cholestasis (PFIC) disease
mechanisms. Top MDR3 is a flippase, translocating phosphatidylcholine
(PC) from the cytosolic leaflet of the canalicular membrane to the leaflet
facing the bile duct lumen. Bile salts are pumped into the canaliculus by
the bile salt export pump (BSEP). Bile salts remove PC from the
canalicular membrane to form mixed micelles containing bile salts, PC
and cholesterol. Middle In PFIC type 2, BSEP is not expressed.
Therefore PC secretion is very low (faint arrow). Bile salts accumulate
in the hepatocyte, cause damage and induce apoptosis. Bile, devoid of bile
salts, cannot release gamma-glutamyltransferase (GGT) from the bile
ducts. Therefore the serum GGT activity in these patients is low, despite
the cholestasis. Bottom In PFIC type 3, MDR3 is not expressed.
Therefore bile salts are pumped into the canaliculus unaccompanied by
PC. Bile without PC is toxic to the bile ducts (bile salts are
membranolytic). Damaged bile ducts proliferate and with the help of bile
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reaction revealed homozygous mutations in the MDR3
mRNA. Genomic DNA analysis of their parents showed
that they are heterozygous for this mutation. A nondiseased
sister of one of the patients is homozygous normal. None of
the two described patients responded to ursodeoxycholic
acid (UDCA) therapy. The authors speculated that patients
with the complete MDR3 defect do not respond to UDCA,
whereas responding patients (about 50% in this disease)
have a partial defect (25,26). Figure 3 shows the so called




Intrahepatic cholestasis of pregnancy (ICP) is characterized
by jaundice, pruritus, a moderate increase in serum bile acids,
a mild elevation of serum transaminases and elevated conju-
gated bilirubin levels. ICP occurs in late pregnancy and dis-
appears after delivery. Women with ICP may have had a
period of pruritus or mild cholestasis during the use of
estrogen-containing contraceptives. ICP usually reappears
during subsequent pregnancies. Stillbirth or premature
births are feared complications. UDCA therapy has a benefi-
cial effect on the disease in the mother and on the outcome
of pregnancy (27-29). The etiology of ICP is unknown. ICP
has been reported to occur in families with BRIC (30) and in
families with PFIC type 3 (31).
DUBIN-JOHNSON SYNDROME
The transport mutant rat provides an animal model for
Dubin-Johnson syndrome. In these rats, the biliary secretion
of conjugated bilirubin, glutathione, glutathione S-conj-
ugates, 3-O-glucuronidated and sulphated bile salts is se-
verely depressed (32,33). When placed on a tryptophan-
containing diet, these rats develop the characteristic black
liver pigment seen in patients with Dubin-Johnson disease
(34). Recently, the molecular defect in these rats has been
elucidated and appears to be a mutation of the c-moat gene
(35,36). Patients with Dubin-Johnson syndrome have a mild
conjugated hyperbilirubinemia, a black pigment in the liver,
a characteristic bromosulphthalein disappearance curve
(with a secondary rise) and an elevated urinary excretion of
coproporphyrin isomer I. It is a mild disease, and patients
with Dubin-Johnson syndrome have a normal life span. Mu-
tations in the cMOAT/MRP2 gene form the basis of the de-
fective cMOAT/MRP2 expression in the canalicular mem-
branes in these patients (37-39). During pregnancy, patients
with Dubin-Johnson syndrome may become deeply jaun-
diced; however, this is caused by a rise in serum bilirubin,
and serum bile salt levels remain normal and signs of cho-
lestasis such as pruritus do not occur (40). This provides evi-
dence against the argument that estrogen metabolites,
which are increased during pregnancy and are secreted into
bile via cMOAT/MRP2, are major factors in the etiology of
ICP. If that were so, patients with Dubin-Johnson syndrome
would be prone to developing ICP, which is not the case.
OTHER GENETIC CHOLESTATIC DISEASES
At least 17 different enzymes are involved in the synthesis of
bile acids. Mutations in some of these enzymes have been de-
scribed as the underlying cause of cholestatic diseases with
variable expression. As with PFIC types 1 and 2, patients
with 3-beta-hydroxy-C27-steroid dehydrogenase/isomerase
deficiency have normal serum GGT-activity, elevated con-
jugated bilirubin levels, increased transaminase activity and
normal serum bile acid levels. It may seem surprising that
these patients have normal serum bile acid levels, but this
occurs because routine assays do not detect the abnormal
bile acids formed in these patients (41,42). Other defects in-
clude those resulting from deficiencies of delta4-3-
oxosteroid-5-beta-reductase and some other enzymes of the
bile acid synthetic pathway. Interestingly, some of the bile
acid intermediate metabolites are severely cholestatic in
that they inhibit the secretion of normal bile acids (43). Re-
cently, Arnon et al (44) reported a cholesterol 7-alpha-
hydroxylase knockout mouse with neonatal cholestasis
caused by toxic monohydroxy bile acids that are synthesized
via the undisturbed cholesterol 27-hydroxylase pathway.
Mutation of this gene in humans is a cause of severe neonatal
liver disease (45).
CONCLUSIONS
Will the patients with genetic cholestasis or their families
benefit from these new insights in bile salt metabolism? Al-
though not practised yet, prenatal diagnosis in families with
an affected child is possible. As for gene therapy, it may seem
too early to speculate, but it is reasonable that the PFIC sub-
types may be amenable to gene therapy if the gene can be ad-
ministered before the liver becomes cirrhotic. Finally,
hepatocyte transplantation has been shown to be a viable
option in mdr2–/– knockout mice (46). Their human coun-
terparts, patients with PFIC type 3, may be candidates for
this elegant potential new therapy.
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